Utah

Mixedstatus since reviewed

Psilocybin has mixed legal status in Utah.1

1. What the law is

Utah's psilocybin route runs through hospitals, and only certain ones. The statute defines a qualifying healthcare system three ways: a privately owned, non-profit, vertically integrated healthcare system operating at least 15 licensed hospitals in the state; a health care system closely affiliated with an institution of higher education listed in Section 53H-1-102; or a health care system closely affiliated with a private postsecondary educational institution as defined in Section 53H-1-101. The drug may be used only under the direct supervision and control of that system and its licensed providers, and only by adults. This is a clinical authorization. It is not a decriminalization, and it is not a route a patient can enter alone. The section protects only conduct that complies with it, nothing leaves the clinical setting, and possession outside it is a Schedule I offense. Whether any program is running is not established by the public record. The report that participating systems owed the Health and Human Services Interim Committee before 1 July 2026 was listed in the Legislature's reporting registry as report id 648, Overdue with no submission, when checked on 17 August 2026. It was still listed there as overdue, with no submission, on 10 November 2026, and the statute attaches that duty only to a system that creates a program. Two 2026 acts sit alongside it. One authorizes a safety and feasibility study of psychedelic-assisted therapy for veterans with treatment-resistant PTSD, naming MDMA, 5-MeO-DMT and psilocybin; it appropriates no money itself, and the study must begin by 1 January 2027 if legislative appropriations together with gifts and donations reach an amount the institute judges sufficient. The other provides that if the federal government schedules an FDA-approved pharmaceutical composition of a Schedule I substance outside Schedule I, that product is scheduled the same way in Utah automatically. No approved psilocybin medicine exists, so nothing changes under it today.

Utah occupies an unusual position in United States psychedelics law: psilocybin remains a Schedule I controlled substance, yet state law provides an enacted clinical pathway. SB 266 (2024), which took effect May 1, 2024 after Governor Cox allowed it to become law without his signature, established a hospital-based pilot permitting licensed providers at qualifying healthcare systems to administer psilocybin and MDMA as behavioral health treatments in supervised clinical settings. The substances may not be taken home and may not be administered to minors; the authorization is repealed on July 1, 2027. In March 2026, Governor Cox signed HB 390, the Veterans PTSD Clinical Research Amendments, which authorizes the Huntsman Mental Health Institute to run a safety and feasibility study of psychedelic-assisted therapy in veterans with treatment-resistant PTSD. The act carries no money of its own, and it lets the study start only once appropriations, gifts and donations add up to an amount the institute judges sufficient, which is why the $1 million usually attached to HB 390 is a separate appropriation that University of Utah Health reports, and why no state record yet shows the study running. The groundwork was laid in 2022, when HB 167 created the Mental Illness Psychotherapy Drug Task Force to study psilocybin and MDMA; its report recommended a cautious, clinically supervised approach. Outside these programs, possession, cultivation, and sale of psilocybin remain criminal offenses in Utah, and no decriminalization or personal-use measure is in effect.

Utah is the unexpected pilot leader among conservative states. Utah did not go to the ballot box. It routed psychedelics through qualifying healthcare systems, a mechanism with built-in institutional accountability that has proven politically durable in a legislature otherwise cautious on drug policy. The next decision points are fixed in statute: a healthcare system that creates a program had to report to the Legislature's Health and Human Services Interim Committee before July 1, 2026, and the section is repealed on July 1, 2027. On November 10, 2026 the Legislature's reporting registry listed that report as overdue, with no submission. HB 390 requires the veterans study to begin by January 1, 2027 if appropriations and donations reach an amount the institute judges sufficient. The near-term trajectory is continued clinical-channel incrementalism rather than broader access.

2. Trials in Utah

Interventional psilocybin trials with at least one site in Utah, as their sponsors filed them with ClinicalTrials.gov, EU CTIS, ISRCTN and ANZCTR. Each row links to the registry record, which sets out who may take part.

3Recruiting or opening
2Active
5Completed
0Closed
10Total

Recruiting or opening counts trials recruiting now, not yet recruiting, or enrolling by invitation. Closed counts trials terminated, suspended, withdrawn or left unverified by their sponsors.

Registry data as of Nov 2026. The table shows all 10 trials, those recruiting now first, then those opening, then the others, latest start date first within each. This site makes no medical claims about psilocybin.
NCT07570654Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder (opens in new tab)Recruiting at UT, OremPhase Phase 2/3Sponsor COMPASS PathwaysStatus RecruitingStart date
NCT07895134Psilocybin for Depression in Veterans (opens in new tab)Site at VA Salt Lake City Health Care System, Salt Lake City, UTPhase Phase 2Sponsor VA Office of Research and DevelopmentStatus Not yet recruitingStart date
NCT06605105Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) (opens in new tab)Site at Cedar Clinical Research, DraperPhase Phase 3Sponsor Cybin IRL LimitedStatus Enrolling by invitationStart date
NCT06564818A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens in new tab)Sites in Murray and OremPhase Phase 3Sponsor Cybin IRL LimitedStatus CompletedStart date
NCT06308653Psilocybin for Major Depressive Disorder (MDD) (opens in new tab)Sites in Draper and MurrayPhase Phase 3Sponsor Usona InstituteStatus Active, not recruitingStart date
NCT05711940Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD (opens in new tab)Sites in Draper and Salt Lake CityPhase Phase 3Sponsor COMPASS PathwaysStatus Active, not recruitingStart date
NCT05624268Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD (opens in new tab)Site at Cedar Clinical Research, DraperPhase Phase 3Sponsor COMPASS PathwaysStatus CompletedStart date
NCT05557643PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout (opens in new tab)Site at Huntsman Mental Health Institute, Salt Lake CityPhase Phase 1Sponsor University of UtahStatus CompletedStart date
NCT04522804Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer (opens in new tab)Site at Huntsman Cancer Institute, Salt Lake CityPhase Phase Early 1Sponsor University of UtahStatus CompletedStart date
NCT03866174A Study of Psilocybin for Major Depressive Disorder (MDD) (opens in new tab)Site at Cedar Clinical Research, DraperPhase Phase 2Sponsor Usona InstituteStatus CompletedStart date

ClinicalTrials.gov data courtesy of the U.S. National Library of Medicine.

3. History

The legal events behind this entry, dated and oldest first. Our own reviews and corrections are listed under Changes to this record.

  1. Governor Cox signs HB 167, creating the Mental Illness Psychotherapy Drug Task Force to study psilocybin and MDMA for mental health treatment.

  2. Legislature passes SB 266; Governor Cox allows the hospital pilot bill to become law without his signature, citing broad legislative support.

    SB 266 takes effect, permitting providers at qualifying healthcare systems to administer psilocybin and MDMA in supervised clinical settings.

    Mixed status takes effect.

  3. Governor Cox signs HB 390, authorizing a safety and feasibility study of psychedelic-assisted therapy in veterans with treatment-resistant PTSD at the Huntsman Mental Health Institute; the statute appropriates nothing and sets a funding condition before the study may begin.

    Statutory deadline for SB 266 pilot providers to report patient outcomes and program data to the Legislature; the pilot sunsets in 2027.

4. Proposed laws

No psilocybin bill is pending. The Legislature's own list of bills passed in the 2026 general session, checked 10 Nov 2026, carries no psychedelic measure other than HB 390, the scheduling act SB 83, and HB 279 and HB 301, which amended and renumbered the behavioral health treatment section, and that session has adjourned. Two clocks are open: the report that participating healthcare systems owed the Health and Human Services Interim Committee before 1 July 2026, registered at le.utah.gov as report id 648, Drugs for Behavioral Health Treatment Report, and listed there as overdue with no submission as at 10 Nov 2026; and the repeal of the authorization on 1 July 2027.

5. Common questions

Are magic mushrooms ("shrooms") legal in Utah?

"Magic mushrooms" and "shrooms" are common names for fungi that contain psilocybin, and this entry states the law on psilocybin itself, which some laws treat separately from the fungus. Psilocybin has mixed legal status in Utah.

Read the law

Utah Code 58-37-309 (Drugs for behavioral health treatment), enacted as 58-37-3.5 by SB 266 (2024) effective 1 May 2024, amended by HB 279 (2026), chapter 183, signed 19 Mar 2026, to add healthcare systems closely affiliated with a private postsecondary educational institution, and renumbered and amended by HB 301 (2026), chapter 362, signed 24 Mar 2026, both effective 6 May 2026: a healthcare system meeting the statutory criteria may include psilocybin or MDMA that is in FDA Phase 3 testing in a behavioral health treatment program, used only under the direct supervision and control of that system and its licensed providers and only by adults. The section is repealed 1 July 2027 by Utah Code 63I-1-258. HB 390 (2026), chapter 196, signed 19 March 2026 and effective 6 May 2026, enacts Utah Code 26B-7-126 authorizing the Huntsman Mental Health Institute to conduct a safety and feasibility study of psychedelic-assisted therapy for veterans with treatment-resistant PTSD; the act appropriates no money itself and is repealed 1 July 2032. SB 83 (2026), chapter 348, signed 24 March 2026 and effective 6 May 2026, adds a subsection to Utah Code 58-37-4, now 58-37-108(3)(b), under which an FDA-approved pharmaceutical composition of a Schedule I substance is deemed scheduled in Utah in the same schedule the federal government assigns it. Outside these provisions psilocybin and psilocyn remain listed in Schedule I, at Utah Code 58-37-108(2)(a)(iii)(Y) and (Z) since chapter 362 of the 2026 General Session renumbered the schedules from 58-37-4.1

Sources

This entry's status is checked against the primary sources below, and the methodology explains how each entry is graded for confidence.

  1. 1.le.utah.gov (opens in new tab) · le.utah.gov
  2. 2.healthcare.utah.edu (opens in new tab) · healthcare.utah.edu

This entry is for information only and is not legal or medical advice. Laws change, and enforcement can differ from the letter of the law, so check the current position against the primary sources above before relying on it.

Changes to this record

7 changes on file, the latest on . Show all

Every change we have made to this record, dated, corrections included. Nothing changes silently.

  1. Correction

    Utah's 2026 session passed two more bills touching the psilocybin treatment law, HB 279 and HB 301, which one field had left out. The law is repealed on July 1, 2027, and no record shows a program operating under it.

  2. Correction

    Utah's entry now names the 2026 law that widened its hospital psilocybin provision. HB 279, signed on 19 March 2026, added healthcare systems closely affiliated with a private postsecondary institution to those that may run a treatment program using psilocybin that is in Phase 3 FDA testing. The entry had credited only the act that renumbered the section. Utah's status is unchanged.

  3. A federal appeals court ruled on 5 October 2026 that a lower court should not have blocked Utah's criminal case against the founder of Singularism, a religion whose ceremony uses psilocybin, and that Utah does not violate religious freedom by letting only qualifying healthcare systems use the drug. The court sent a further religious-freedom argument back to the trial court to decide. A separate order under Utah's own religious-freedom law, which bars interference with the group's religious use of psilocybin, was not appealed, and the appeals court expressed no opinion on it. Psilocybin's legal status in Utah is unchanged.

  4. Correction

    Utah's entry now cites the renumbered sections of the state's drug law, and says when the overdue-report finding was last seen, since the registry that showed it can no longer be reached. The hospital-based psilocybin authorization is unchanged.

  5. Correction

    Utah's entry overstated two things. The law allows a wider class of health systems than we described, following a 2026 renumbering, and we called the pilot operational when no state record shows that it is. The report the Legislature required by 1 July 2026 is registered as overdue and unfiled.

  6. Correction

    Utah's entry now records HB 390 (2026), which authorizes a study of psychedelic-assisted therapy for veterans, and the effective date of the 2024 clinical authorization is corrected to May 1, 2024. The status is unchanged.

  7. Correction

    Utah's entry now records the 2026 scheduling act that would follow a federal rescheduling of an approved psilocybin medicine, and corrects the description of the veterans research law, which authorizes a study but appropriates no money itself.

Cite this recordUS-UT-001

Psilocybin Media Group. "Utah: psilocybin legal status." The Psilocybin Record, accession US-UT-001, version of 10 Nov 2026. https://psilocybinlegalization.com/record/utah

Record 100 of 106 · Last reviewed US-UT-001